

---

# Committee Report

**CONSENT CALENDAR**

**March 20, 2019**

**HOUSE OF REPRESENTATIVES**

**REPORT OF COMMITTEE**

**The Committee on Commerce and Consumer Affairs to  
which was referred HB 670-FN,**

**AN ACT relative to the cost of prescription drugs.**

**Having considered the same, report the same with the  
following amendment, and the recommendation that the  
bill OUGHT TO PASS WITH AMENDMENT.**

**Rep. Garrett Muscatel**

**FOR THE COMMITTEE**

## COMMITTEE REPORT

Committee:	Commerce and Consumer Affairs
Bill Number:	HB 670-FN
Title:	relative to the cost of prescription drugs.
Date:	March 20, 2019
Consent Calendar:	CONSENT
Recommendation:	OUGHT TO PASS WITH AMENDMENT 2019-0893h

### STATEMENT OF INTENT

This bill requires health carriers to have access to information about prescription drug spending for their covered members. The amendment clarifies that the data need not be kept directly on the insurer's own systems but need only be readily available and accessible. This language has also been agreed to by various industry groups involved. This bill is necessary because the Insurance Department requests this data from insurance companies in order to study changes in prescription drug spending, but the department currently does not always receive this information. By requiring this information to be accessible, the Insurance Department can ensure that it will receive timely information from carriers to better understand health care spending in our state.

Vote 20-0.

Rep. Garrett Muscatel  
FOR THE COMMITTEE

Original: House Clerk  
Cc: Committee Bill File

## CONSENT CALENDAR

Commerce and Consumer Affairs

**HB 670-FN**, relative to the cost of prescription drugs. **OUGHT TO PASS WITH AMENDMENT.**

Rep. Garrett Muscatel for Commerce and Consumer Affairs. This bill requires health carriers to have access to information about prescription drug spending for their covered members. The amendment clarifies that the data need not be kept directly on the insurer's own systems but need only be readily available and accessible. This language has also been agreed to by various industry groups involved. This bill is necessary because the Insurance Department requests this data from insurance companies in order to study changes in prescription drug spending, but the department currently does not always receive this information. By requiring this information to be accessible, the Insurance Department can ensure that it will receive timely information from carriers to better understand health care spending in our state. **Vote 20-0.**

Original: House Clerk

Cc: Committee Bill File

This bill requires health carriers to have access to information about prescription drug spending for their covered members. The amendment clarifies that the data need not be kept directly on the insurer's own systems but need only be readily available and accessible. This language has also been agreed to by various industry groups involved. This bill is necessary because the insurance department requests this data from insurance companies in order to study changes in prescription drug spending, but the department currently is not receiving this information. By requiring this information to be accessible, the insurance department can ensure that it will receive timely information from carriers to better understand health care spending in our state.

Best,

Garrett

---

Garrett Muscatel  
State Representative, Hanover and Lyme  
(805)750-9973  
Dartmouth '20

## Stapler, Carol

---

**From:** Garrett Muscatel <repmuscatel@gmail.com>  
**Sent:** Wednesday, March 13, 2019 10:38 AM  
**To:** Stapler, Carol  
**Subject:** Committee Reports

Hey Carol,

Here are my remaining committee reports.

656 2/19

This bill establishes a commission to study financial incentives between insurance companies, pharmacy benefit managers, and pharmaceutical manufacturers on drug prices and insurance premiums. The committee heard that there is a stunning lack of transparency in how insured individuals get their prescription drugs, and it came about as a recommendation from last year's commission which studied this industry with a broader lens. With the skyrocketing costs of prescription drugs, removing the veil from this complicated system will allow us to better understand how financial incentives, ranging from rebates to PBMs from manufacturers to copay coupons for consumers at the pharmacy counter, impact these rising costs. With a better understanding of this process, this commission will be able to suggest future legislation improve the market for prescription drugs in this state. The committee feels that more information will be incredibly valuable to understanding how financial incentives contribute the rising costs of drugs.

657 2/19

As amended, this bill provides an exception process for an individual who is on a low cost drug to continue to take that drug if it is taken off the formulary. The committee heard that a fellow representative testified about an inability to stay on a low cost drug after it was taken off their formulary, and this bill addresses that concern by clarifying and expanding an existing exception process. This process will be beneficial to consumers because using lower cost drugs will help to bring down premiums, and this exception process was agreed to as beneficial by various industry groups involved. The committee believes that this bill fixes a loophole in the low cost drug approval process and allows individuals to continue to use their drugs in the event they are taken off their formulary.

670 2/19

Ready  
DO 670  
WEdoK

Rep. Muscatel, Graf. 12  
March 7, 2019  
2019-0893h  
01/05

Amendment to HB 670-FN

1 Amend RSA 420-J:7-b, XI as inserted by section 1 of the bill by replacing it with the following:

2

3 XI. Health carriers shall have access to or maintain within their data systems amounts paid  
4 to pharmacies and other health care providers for all prescription drugs on behalf of their covered  
5 members. Carriers shall have access to or maintain a record of any amounts due to the pharmacy  
6 from the covered member in the form of cost sharing, such as copayments, deductibles, or  
7 coinsurance. The health carrier shall be responsible for assuring timely access to this information  
8 even when the prescription drug benefit is administered by a pharmacy benefit manager or similar  
9 entity.

# Voting Sheets



**HOUSE COMMITTEE ON COMMERCE AND CONSUMER AFFAIRS**

**EXECUTIVE SESSION on HB 670-FN**

**BILL TITLE:** relative to the cost of prescription drugs.

**DATE:** March 8, 2019

**LOB ROOM:** 302

**MOTIONS: OUGHT TO PASS WITH AMENDMENT**

Moved by Rep. Muscatel                      Seconded by Rep. Butler                      AM Vote: 20-0

Amendment # 2019-0893h

Moved by Rep. Muscatel                      Seconded by Rep. Butler                      Vote: 20-0

**CONSENT CALENDAR: YES**

**Statement of Intent:**                      Refer to Committee Report

Respectfully submitted,

Rep Constance Van Houten, Acting Clerk

HOUSE COMMITTEE ON COMMERCE AND CONSUMER AFFAIRS

EXECUTIVE SESSION on HB 670-FN

BILL TITLE: relative to the cost of prescription drugs.

DATE: 3-8-9

LOB ROOM: 302

MOTION: (Please check one box)

- OTP
- ITL
- Retain (1<sup>st</sup> year)
- Adoption of Amendment # 0893h (if offered)
- Interim Study (2nd year)

Moved by Rep. Muscatel Secoded by Rep. Butler Vote: 20-0

MOTION: (Please check one box)

- OTP
- OTP/A
- ITL
- Retain (1<sup>st</sup> year)
- Adoption of Amendment # (if offered)
- Interim Study (2nd year)

Moved by Rep. Muscatel Secoded by Rep. Butler Vote: 20-0

MOTION: (Please check one box)

- OTP
- OTP/A
- ITL
- Retain (1<sup>st</sup> year)
- Adoption of Amendment # (if offered)
- Interim Study (2nd year)

Moved by Rep. Secoded by Rep. Vote:

MOTION: (Please check one box)

- OTP
- OTP/A
- ITL
- Retain (1<sup>st</sup> year)
- Adoption of Amendment # (if offered)
- Interim Study (2nd year)

Moved by Rep. Secoded by Rep. Vote:

CONSENT CALENDAR: YES NO

Minority Report? Yes No If yes, author, Rep: Motion

Respectfully submitted: Constance A. Hester Rep. Rebecca McBeath, Clerk



2019 SESSION

Commerce and Consumer Affairs

Bill #: 670 Motion: Adopt AM #: 0893h Exec Session Date: 2/8/2019

<u>Members</u>	<u>YEAS</u>	<u>Nays</u>	<u>NV</u>
Butler, Edward A. Chairman	X		
Williams, Kermit R. Vice Chairman	X		
Gidge, <del>Kenneth N.</del> <i>Schutz</i>	X		
Abel, Richard M.	X		
McBeath, <del>Rebecca Susan Clerk</del> <i>Rung</i>	X		
Bartlett, Christy D.	X		
Herbert, Christopher J.	X		
Van Houten, Constance	X		
Fargo, <del>Kristina M.</del> <i>McConnell</i>	X		
Indruk, Greg L.	X		
Muscatel, Garrett D.	X		
Weston, Joyce	X		
Hunt, John B.	X		
Sanborn, <del>Laurie J.</del> <i>BURNS</i>	X		
Osborne, Jason M.	X		
Costable, Michael	X		
Plumer, John R.	X		
Barnes, Arthur E.	X		
Potucek, John M.	X		
Warden, <del>Mark</del> <i>Spillane</i>	X		
<b>TOTAL VOTE:</b> <u>20-0</u>			



2019 SESSION

Commerce and Consumer Affairs

Bill #: 670-FN Motion: OTPA <sup>2019-</sup> AM #: 0893h Exec Session Date: 3/8/2019

<u>Members</u>	<u>YEAS</u>	<u>Nays</u>	<u>NV</u>
Butler, Edward A. Chairman	X		
Williams, Kermit R. Vice Chairman	X		
Gidge, Kenneth N. <i>Schutz</i>	X		
Abel, Richard M.	X		
McBeath, Rebecca Susan Clerk <i>Rung</i>	X		
Bartlett, Christy D.	X		
Herbert, Christopher J.	X		
Van Houten, Constance	X		
Fargo, Kristina M. <i>McConnell</i>	X		
Indruk, Greg L.	X		
Muscatel, Garrett D.	X		
Weston, Joyce	X		
Hunt, John B.	X		
Sanborn, Laurie J. <i>BURNS</i>	X		
Osborne, Jason M.	X		
Costable, Michael	X		
Plumer, John R.	X		
Barnes, Arthur E.	X		
Potucek, John M.	X		
Warden, Mark <i>Spillane</i>	X		
<b>TOTAL VOTE:</b> <u>20-0</u>			

Rep. Muscatel, Graf. 12  
March 7, 2019  
2019-0893h  
01/05

Amendment to HB 670-FN

1 Amend RSA 420-J:7-b, XI as inserted by section 1 of the bill by replacing it with the following:

2

3 XI. Health carriers shall have access to or maintain within their data systems amounts paid  
4 to pharmacies and other health care providers for all prescription drugs on behalf of their covered  
5 members. Carriers shall have access to or maintain a record of any amounts due to the pharmacy  
6 from the covered member in the form of cost sharing, such as copayments, deductibles, or  
7 coinsurance. The health carrier shall be responsible for assuring timely access to this information  
8 even when the prescription drug benefit is administered by a pharmacy benefit manager or similar  
9 entity.

# Sub-Committee Minutes



HOUSE COMMITTEE ON COMMERCE AND CONSUMER AFFAIRS

SUBCOMMITTEE WORK SESSION on HB 670-FN

BILL TITLE: relative to the cost of prescription drugs.

DATE: 3-8-19

Subcommittee Members: Reps. Butler, Williams, McBeath, Gidge, Abel, Bartlett, Herbert, Van Houten, Fargo, Indruk, Muscatel, Weston, Hunt, Sanborn, J. Osborne, Costable, Plumey, Barnes, Potucek and Warden

Comments and Recommendations:

Amendment reduced redundancy and everyone was satisfied with language

MOTIONS: (OTP) OTP/A, ITL, Retained (1st Yr), Interim Study (2nd Yr) (Please circle one)

Moved by Rep. Potucek Seconded by Rep. Barnes AM Vote: 5-0

Adoption of Amendment # 0893h

Moved by Rep. Seconded by Rep. Vote:

Amendment Adopted Amendment Failed

MOTIONS: Muscatel (OTP/A) OTP/A, ITL, Retained (1st Yr), Interim Study (2nd Yr) (Please circle one)

Moved by Rep. Muscatel Seconded by Rep. Potucek AM Vote: 5-0

Adoption of Amendment #

Moved by Rep. Seconded by Rep. Vote:

Amendment Adopted Amendment Failed

Respectfully submitted,

Rep. Subcommittee Chairman/Clerk



HOUSE COMMITTEE ON COMMERCE AND CONSUMER AFFAIRS

**SUBCOMMITTEE WORK SESSION** on HB 670-FN

**BILL TITLE:** relative to the cost of prescription drugs.

**DATE:** March 6, 2019

**Subcommittee Members:** Reps. Butler, Bartlett, Fargo, Muscatel, Weston, Hunt, Barnes and Potucek

**Comments and Recommendations:** The carrier shall have access. Rep. Butler - amendment to.

Respectfully submitted,

Rep. Edward Butler  
Subcommittee Chairman

HOUSE COMMITTEE ON COMMERCE AND CONSUMER AFFAIRS

SUBCOMMITTEE WORK SESSION on HB 670-FN

BILL TITLE: relative to the cost of prescription drugs.

DATE: 3/6/19

Subcommittee Members: Reps. Butler, Williams, McBeath, Gidge, Abel, Bartlett, Herbert, Van Houten, Fargo, Indruk, Muscatel, Weston, Hunt, Sanborn, J. Osborne, Costable, Plumer, Barnes, Potucek and Warden

Comments and Recommendations:

- The carrier shall have access"
Rep Butler - Amendment 10

MOTIONS: OTP, OTP/A, ITL, Retained (1st Yr), Interim Study (2nd Yr)
(Please circle one)

Moved by Rep. Seconded by Rep. AM Vote:

Adoption of Amendment #

Moved by Rep. Seconded by Rep. Vote:

Amendment Adopted Amendment Failed

MOTIONS: OTP, OTP/A, ITL, Retained (1st Yr), Interim Study (2nd Yr)
(Please circle one)

Moved by Rep. Seconded by Rep. AM Vote:

Adoption of Amendment #

Moved by Rep. Seconded by Rep. Vote:

Amendment Adopted Amendment Failed

Respectfully submitted,

Rep. Kristina Fargo
Subcommittee Chairman/Clerk

HOUSE COMMITTEE ON COMMERCE AND CONSUMER AFFAIRS

**SUBCOMMITTEE WORK SESSION** on HB 670-FN

**BILL TITLE:** relative to the cost of prescription drugs.

**DATE:** February 21, 2019

**Subcommittee Members:** Reps. Butler, Bartlett, Fargo, Muscatel, Weston, Hunt, Barnes and Potucek

**Comments and Recommendations:**

Respectfully submitted,

Rep. Edward Butler  
Subcommittee Chairman

HOUSE COMMITTEE ON COMMERCE AND CONSUMER AFFAIRS

**SUBCOMMITTEE WORK SESSION** on HB 670-FN

**BILL TITLE:** relative to the cost of prescription drugs.

**DATE:** 2-21-19

**Subcommittee Members:** Reps. Butler, Williams, McBeath, Gidge, Abel, Bartlett, Herbert, Van Houten, Fargo, Indruk, Muscatel, Weston, Hunt, Sanborn, J. Osborne, Costable, Plumer, Barnes, Potucek and Warden

**Comments and Recommendations:**

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**MOTIONS:** OTP, OTP/A, ITL, Retained (1st Yr), Interim Study (2nd Yr)  
(Please circle one)

Moved by Rep. \_\_\_\_\_ Seconded by Rep. \_\_\_\_\_ AM Vote: \_\_\_\_\_

Adoption of Amendment # \_\_\_\_\_

Moved by Rep. \_\_\_\_\_ Seconded by Rep. \_\_\_\_\_ Vote: \_\_\_\_\_

\_\_\_\_\_ Amendment Adopted \_\_\_\_\_ Amendment Failed

**MOTIONS:** OTP, OTP/A, ITL, Retained (1st Yr), Interim Study (2nd Yr)  
(Please circle one)

Moved by Rep. \_\_\_\_\_ Seconded by Rep. \_\_\_\_\_ AM Vote: \_\_\_\_\_

Adoption of Amendment # \_\_\_\_\_

Moved by Rep. \_\_\_\_\_ Seconded by Rep. \_\_\_\_\_ Vote: \_\_\_\_\_

\_\_\_\_\_ Amendment Adopted \_\_\_\_\_ Amendment Failed

Respectfully submitted,

Rep. \_\_\_\_\_  
Subcommittee Chairman/Clerk

# Hearing Minutes

HOUSE COMMITTEE ON COMMERCE AND CONSUMER AFFAIRS

PUBLIC HEARING ON HB 670-FN

BILL TITLE: relative to the cost of prescription drugs.

DATE: February 19, 2019

LOB ROOM: 302 Time Public Hearing Called to Order: 1:40 p.m.

Time Adjourned: 1:54 p.m.

Committee Members: Reps. Butler, Williams, McBeath, Gidge, Abel, Bartlett, Herbert, Van Houten, Fargo, Indruk, Muscatel, Weston, Hunt, Sanborn, J. Osborne, Costable, Plumer, Barnes, Potucek and Warden

Bill Sponsors:

Rep. Butler  
Sen. Sherman

Rep. Marsh

Rep. Knirk

TESTIMONY

\* Use asterisk if written testimony and/or amendments are submitted.

Sponsor Rep. Butler - Sponsor  
Introduction to bill

Tyler Branner – NH Insurance Department

- Already have an all payer claims database.
- Carrier doesn't know what gets paid to pharmacy.
- How would they determine the lowest price after co-pay?
- Carrier already maintains basic information.

Heidi Kröll – A.H.I.P.

Opposed – Reasons below:

- Don't understand how this differs from what they do today
- Don't understand how this data would be used
- They do not have complaints from carriers about PBMs today.

Holly Stevens – New Futures

- Strongly Supports
- Testimony Included
- No questions

Rep. Barnes read the blue sheet  
Vice Chair Williams adjourned the hearing

Respectfully submitted,

Rep. Kristina Fargo, Acting Clerk

HOUSE COMMITTEE ON COMMERCE AND CONSUMER AFFAIRS

PUBLIC HEARING ON HB 670-FN

BILL TITLE: relative to the cost of prescription drugs.

DATE: 2-19-19

ROOM: 302

Time Public Hearing Called to Order: 1:40

Time Adjourned: 1:54

(please circle if present)

Committee Members: Reps. Butler, Williams, McBeath, Gidge, Abel, Bartlett, Herbert, Van Houten, Fargo, Indruk, Muscatel, Weston, Hunt, Sanborn, J. Osborne, Costable, Plumer, Barnes, Potucek and Warden

Bill Sponsors:

Rep. Butler  
Sen. Sherman

Rep. Marsh

Rep. Knirk

① Ed Butler

TESTIMONY

\* Use asterisk if written testimony and/or amendments are submitted.

~~① Tyler Branner - NH~~

② Tyler Branner - NH

③ Heidi Kroll -

④ Holly Stevens -

Empty lined area for additional testimony or amendments.

Tuesday, February 19<sup>th</sup>, 2019

Public Hearings

Vice Chair Williams called the hearing to

**HB 670** – This bill requires insurance carriers to maintain certain information relative to prescription drug costs within their data systems for purposes of the managed care law.

Sponsor Rep. Butler - Sponsor

Introduction to bill

Tyler Branner – NH Insurance Department

- Already have an all payer claims database.
- Carrier doesn't know what gets paid to pharmacy.
- How would they determine the lowest price after co-pay?
- Carrier already maintains basic information.

Heidi Kroll – A.H.I.P.

Opposed – Reasons below:

- Don't understand how this differs from what they do today
- Don't understand how this data would be used
- They do not have complaints from carriers about PBMs today.

Holly Stevens – New Futures

- Strongly Supports
- Testimony Included
- No questions

Rep. Barnes read the blue sheet

Vice Chair Williams adjourned the hearing

Rep. Kristina Fargo



Butler

670 - Relative to gathering data regarding drug costs as policy makers. We do not get consistently

Tina's  
Notes

Branner

- All payer claims database  
Carrier doesn't know what gets paid. <sup>to pharmacy.</sup> lowest price after co-pay.  
Carrier maintains basic info - spread

Q-KW - Does this bill create problem for reporting? what details are known for what is paid?

Q-KW - How do rebates apply to this.

A - This bill does not address rebates

Q-RA - Would this add any cost to department?

A - No - we already manage

---

H. Krull - Opposed.

How does this differ from what they do today?

How would this data be used?

- No ~~complaints~~ complaints today from carriers ~~(~~about~~)~~  
about PDM's

---

Holly Stevens - New Futures <sup>Testimony</sup>  
↳ strongly supports bill

---

Butler

HB670

Connie's  
Notes

bill is info gathering  
requested in past - inconsistently  
reported

---

Brannen

ins. co. ~~brings~~

certain req to PBM

enforcing laws, but co. can't

tell because PBM has

data, PBM should

ins. co. <sup>or</sup> give benefit of lowest  
amount to patient

carrier has to go to PBM for  
data, but doesn't want to  
tell carrier

PBM has to tell carrier under  
this bill

Q-KW-

ins. co not aware of what PBM  
paying pharmacy - problem  
to happen

A - carrier often knows spread  
amount, just what being charged -  
doesn't want to tell

Q-KW - rebates?

A - not addressed directly in this  
bill

Q-RA - if enacted, add any costs to  
dept. - adequate staff

A - makes things simpler

---

Heidi Kroll, AHIP -

opposed

concern - how def from what

already doing admin

burdens? where data to go

looks forward to subcom

PKW - good for members as get data from IBM?

A - never heard concern from carriers

Jelly Stevens - New Futures  
support



# Testimony

#4

February 19, 2018

The Honorable Edward Butler, Chair  
House Commerce and Consumer Affairs Committee  
Legislative Office Building Room 302  
Concord, NH 03301

Re: New Futures' support of HB 670-FN

Dear Chairman Butler and Members of the Committee:

New Futures appreciates the opportunity to testify in support of HB 670-FN, which would require insurance carriers to maintain records relating to cost sharing and amounts paid to pharmacies and other health care providers for all prescription drugs on behalf of their members. New Futures is a nonpartisan, nonprofit organization that advocates, educates and collaborates to improve the health and wellness of all New Hampshire residents. In this role, we work extensively with policy makers, health care providers and families to increase access to quality, affordable health care throughout the Granite State. In recent years, with the increasing cost of pharmaceutical drug prices, including generics that have been on the market for decades, transparency in the pharmaceutical industry is of concern to New Futures.

Last summer, I participated in the HB 1418 Commission to Study Greater Transparency in Pharmaceutical Costs and Drug Rebate Programs (Commission). Although the Commission heard testimony from many stakeholders, it did not have enough time to complete its study. The Commission was not able to come to a consensus around any legislative recommendations; however, individual Commission members did make suggestions for legislative change. One thing that was clear from the testimony is that increasing drug prices are not the result of any one entity type (i.e. manufacturers, PBM, insurers, etc.), but due to what is going on in the entire system. The problem is, the system is very opaque, and no one can see what is truly causing the skyrocketing prices.

One of the legislative suggestions that resulted from the Commission was to gather information on amounts paid for prescription drugs by insurers and the out of pocket costs incurred by their members, which HB 670-FN would do. PBM state that they save money for the insurers, which keeps premiums down. However, it is unclear if this really is the case. If the New Hampshire Insurance Department (NHID) had access to data regarding amounts paid by insurers for drugs and the amount of out of pocket costs members incur, it could assess whether PBM save money or end up costing insurers and their members more, thus leading to higher premiums and out of pocket costs for consumers. It could also assess compliance with NH law that a consumer must be charged the lesser of the applicable co-payment, the contracted price, or the cash price.<sup>1</sup>

Until a governmental agency, such as the NHID, can begin looking at the business practices of manufactures, PBMs, insurers, wholesalers, and pharmacies to see what is driving the high cost of drugs, it will be unclear what legislative fixes are appropriate. Greater transparency into the entire system is necessary so that policy makers know how to remedy the problem, thus making

<sup>1</sup> Ins 7204.02(d)

pharmaceutical drugs more affordable to those who need them. HB 670-FN is one step and one bill among many this session that will lead to greater transparency. For those reasons, New Futures urges the Committee vote HB 670-FN ought to pass.

Please do not hesitate to contact me if you have any questions.

Respectfully submitted,



Holly A. Stevens, Esq.  
Health Policy Coordinator



Rep. Muscatel, Graf. 12  
March 7, 2019  
2019-0893h  
01/05

Amendment to HB 670-FN

1 Amend RSA 420-J:7-b, XI as inserted by section 1 of the bill by replacing it with the following:

2

3 XI. Health carriers shall have access to or maintain within their data systems amounts paid  
4 to pharmacies and other health care providers for all prescription drugs on behalf of their covered  
5 members. Carriers shall have access to or maintain a record of any amounts due to the pharmacy  
6 from the covered member in the form of cost sharing, such as copayments, deductibles, or  
7 coinsurance. The health carrier shall be responsible for assuring timely access to this information  
8 even when the prescription drug benefit is administered by a pharmacy benefit manager or similar  
9 entity.

DRAFT

# Bill as Introduced

STATE OF NEW HAMPSHIRE

*In the Year of Our Lord Two Thousand Nineteen*

AN ACT                   relative to the cost of prescription drugs.

*Be it Enacted by the Senate and House of Representatives in General Court convened:*

1           1 New Paragraph; Managed Care Law: Prescription Drugs. Amend RSA 420-J:7-b by inserting  
2 after paragraph X the following new paragraph:

3           XI. Health carriers shall maintain within their data systems amounts paid to pharmacies  
4 and other health care providers for all prescription drugs on behalf of their covered members.  
5 Carriers shall maintain a record of any amounts due to the pharmacy from the covered member in  
6 the form of cost sharing, such as copayments, deductibles, or coinsurance. The health carrier shall  
7 be responsible for maintaining this information in its own data system even when the prescription  
8 drug benefit is administered by a pharmacy benefit manager or similar entity.

9           2 Effective Date. This act shall take effect 60 days after its passage.

HB 670-FN- FISCAL NOTE  
AS INTRODUCED

AN ACT relative to the cost of prescription drugs.

FISCAL IMPACT:  State  County  Local  None

STATE:	Estimated Increase / (Decrease)			
	FY 2020	FY 2021	FY 2022	FY 2023
Appropriation	\$0	\$0	\$0	\$0
Revenue	Indeterminable	Indeterminable	Indeterminable	Indeterminable
Expenditures	Indeterminable	Indeterminable	Indeterminable	Indeterminable
<i>Funding Source:</i>	<input checked="" type="checkbox"/> General	<input type="checkbox"/> Education	<input type="checkbox"/> Highway	<input type="checkbox"/> Other

**METHODOLOGY:**

This bill requires insurers writing managed care coverage to maintain data relative to prescription drug benefits even if such coverage is managed by a pharmacy benefit manager (PBM). The Insurance Department states the bill's impact on insurers' administrative costs is unclear, as is the impact on the contracts insurers maintain with PBMs. As such, the bill will have an indeterminable impact on state insurance premium tax revenue.

The Department of Health and Human Services states that although the bill will have no direct impact on expenditures, Medicaid managed care organizations may seek to pass along any resulting cost increases to the Department through the contracting process. The extent of any such costs is indeterminable.

The Department of Administrative Services states the bill will have no fiscal impact.

**AGENCIES CONTACTED:**

Insurance Department, and Departments of Health and Human Services and Administrative Services